18F-THK5351 Positron Emission Tomography Imaging in Neurodegenerative Tauopathies

Michinori Ezura; Akio Kikuchi; Nobuyuki Okamura; Aiko Ishiki; Takafumi Hasegawa; Ryuichi Harada; Shoichi Watanuki; Yoshihito Funaki; Kotaro Hiraoka; Toru Baba; Naoto Sugeno; Shun Yoshida; Junpei Kobayashi; Michiko Kobayashi; Ohito Tano; Shun Ishiyama; Takaaki Nakamura; Ichiro Nakashima; Shunji Mugikura; Ren Iwata; Yasuyuki Taki; Katsutoshi Furukawa; Hiroyuki Arai; Shozo Furumoto; Manabu Tashiro; Kazuhiko Yanai; Yukitsuka Kudo; Atsushi Takeda; Masashi Aoki

doi:10.3389/fnagi.2021.761010

¹⁸F-THK5351 Positron Emission Tomography Imaging in Neurodegenerative Tauopathies

Michinori Ezura, Akio Kikuchi, Nobuyuki Okamura, Aiko Ishiki, Takafumi Hasegawa, Ryuichi Harada, Shoichi Watanuki, Yoshihito Funaki, Kotaro Hiraoka, Toru Baba, Naoto Sugeno, Shun Yoshida, Junpei Kobayashi, Michiko Kobayashi, Ohito Tano, Shun Ishiyama, Takaaki Nakamura, Ichiro Nakashima, Shunji Mugikura, Ren IwataYasuyuki Taki, Katsutoshi Furukawa, Hiroyuki Arai, Shozo Furumoto, Manabu Tashiro, Kazuhiko Yanai, Yukitsuka Kudo, Atsushi Takeda, Masashi Aoki

Research output: Contribution to journal › Article › peer-review

21 Citations (Scopus)

Abstract

Introduction: We aimed to determine whether in vivo tau deposits and monoamine oxidase B (MAO-B) detection using ¹⁸F-THK5351 positron emission tomography (PET) can assist in the differential distribution in patients with corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), and Alzheimer’s disease (AD) and whether ¹⁸F-THK5351 retention of lesion sites in CBS and PSP can correlate with clinical parameters. Methods: ¹⁸F-THK5351 PET was performed in 35 participants, including 7, 9, and 10 patients with CBS, PSP, and AD, respectively, and 9 age-matched normal controls. In CBS and PSP, cognitive and motor functions were assessed using the Montreal Cognitive Assessment, Addenbrooke’s Cognitive Examination–Revised, and Frontal Assessment Battery, Unified Parkinson’s Disease Rating Scale Motor Score, and PSP Rating Scale. Results: ¹⁸F-THK5351 retention was observed in sites susceptible to disease-related pathologies in CBS, PSP, and AD. ¹⁸F-THK5351 uptake in the precentral gyrus clearly differentiated patients with CBS from those with PSP and AD. Furthermore, ¹⁸F-THK5351 uptake in the inferior temporal gyrus clearly differentiated patients with AD from those with CBS and PSP. Regional ¹⁸F-THK5351 retention was associated with the cognitive function in CBS and PSP. Conclusion: Measurement of the tau deposits and MAO-B density in the brain using ¹⁸F-THK5351 may be helpful for the differential diagnosis of tauopathies and for understanding disease stages.

Original language	English
Article number	761010
Journal	Frontiers in Aging Neuroscience
Volume	13
DOIs	https://doi.org/10.3389/fnagi.2021.761010
Publication status	Published - 2021 Nov 29

Keywords

Alzheimer’s disease (AD)
F-THK5351
corticobasal syndrome (CBS)
monoamine oxidase B (MAO-B)
positron emission tomography (PET)
progressive supranuclear palsy (PSP)
tau deposits
tauopathy

Access to Document

10.3389/fnagi.2021.761010

Cite this

Ezura, M., Kikuchi, A., Okamura, N., Ishiki, A., Hasegawa, T., Harada, R., Watanuki, S., Funaki, Y., Hiraoka, K., Baba, T., Sugeno, N., Yoshida, S., Kobayashi, J., Kobayashi, M., Tano, O., Ishiyama, S., Nakamura, T., Nakashima, I., Mugikura, S., ... Aoki, M. (2021). ¹⁸F-THK5351 Positron Emission Tomography Imaging in Neurodegenerative Tauopathies. Frontiers in Aging Neuroscience, 13, Article 761010. https://doi.org/10.3389/fnagi.2021.761010

@article{ed4d6c796b634ff7925e0641ea272152,

title = "18F-THK5351 Positron Emission Tomography Imaging in Neurodegenerative Tauopathies",

abstract = "Introduction: We aimed to determine whether in vivo tau deposits and monoamine oxidase B (MAO-B) detection using 18F-THK5351 positron emission tomography (PET) can assist in the differential distribution in patients with corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), and Alzheimer{\textquoteright}s disease (AD) and whether 18F-THK5351 retention of lesion sites in CBS and PSP can correlate with clinical parameters. Methods: 18F-THK5351 PET was performed in 35 participants, including 7, 9, and 10 patients with CBS, PSP, and AD, respectively, and 9 age-matched normal controls. In CBS and PSP, cognitive and motor functions were assessed using the Montreal Cognitive Assessment, Addenbrooke{\textquoteright}s Cognitive Examination–Revised, and Frontal Assessment Battery, Unified Parkinson{\textquoteright}s Disease Rating Scale Motor Score, and PSP Rating Scale. Results: 18F-THK5351 retention was observed in sites susceptible to disease-related pathologies in CBS, PSP, and AD. 18F-THK5351 uptake in the precentral gyrus clearly differentiated patients with CBS from those with PSP and AD. Furthermore, 18F-THK5351 uptake in the inferior temporal gyrus clearly differentiated patients with AD from those with CBS and PSP. Regional 18F-THK5351 retention was associated with the cognitive function in CBS and PSP. Conclusion: Measurement of the tau deposits and MAO-B density in the brain using 18F-THK5351 may be helpful for the differential diagnosis of tauopathies and for understanding disease stages.",

keywords = "Alzheimer{\textquoteright}s disease (AD), F-THK5351, corticobasal syndrome (CBS), monoamine oxidase B (MAO-B), positron emission tomography (PET), progressive supranuclear palsy (PSP), tau deposits, tauopathy",

author = "Michinori Ezura and Akio Kikuchi and Nobuyuki Okamura and Aiko Ishiki and Takafumi Hasegawa and Ryuichi Harada and Shoichi Watanuki and Yoshihito Funaki and Kotaro Hiraoka and Toru Baba and Naoto Sugeno and Shun Yoshida and Junpei Kobayashi and Michiko Kobayashi and Ohito Tano and Shun Ishiyama and Takaaki Nakamura and Ichiro Nakashima and Shunji Mugikura and Ren Iwata and Yasuyuki Taki and Katsutoshi Furukawa and Hiroyuki Arai and Shozo Furumoto and Manabu Tashiro and Kazuhiko Yanai and Yukitsuka Kudo and Atsushi Takeda and Masashi Aoki",

note = "Publisher Copyright: Copyright {\textcopyright} 2021 Ezura, Kikuchi, Okamura, Ishiki, Hasegawa, Harada, Watanuki, Funaki, Hiraoka, Baba, Sugeno, Yoshida, Kobayashi, Kobayashi, Tano, Ishiyama, Nakamura, Nakashima, Mugikura, Iwata, Taki, Furukawa, Arai, Furumoto, Tashiro, Yanai, Kudo, Takeda and Aoki.",

year = "2021",

month = nov,

day = "29",

doi = "10.3389/fnagi.2021.761010",

language = "English",

volume = "13",

journal = "Frontiers in Aging Neuroscience",

issn = "1663-4365",

publisher = "Frontiers Media SA",

}

Ezura, M, Kikuchi, A, Okamura, N, Ishiki, A, Hasegawa, T, Harada, R, Watanuki, S, Funaki, Y , Hiraoka, K, Baba, T, Sugeno, N, Yoshida, S, Kobayashi, J, Kobayashi, M, Tano, O, Ishiyama, S, Nakamura, T, Nakashima, I, Mugikura, S, Iwata, R, Taki, Y, Furukawa, K, Arai, H, Furumoto, S , Tashiro, M, Yanai, K, Kudo, Y, Takeda, A & Aoki, M 2021, '¹⁸F-THK5351 Positron Emission Tomography Imaging in Neurodegenerative Tauopathies', Frontiers in Aging Neuroscience, vol. 13, 761010. https://doi.org/10.3389/fnagi.2021.761010

TY - JOUR

T1 - 18F-THK5351 Positron Emission Tomography Imaging in Neurodegenerative Tauopathies

AU - Ezura, Michinori

AU - Kikuchi, Akio

AU - Okamura, Nobuyuki

AU - Ishiki, Aiko

AU - Hasegawa, Takafumi

AU - Harada, Ryuichi

AU - Watanuki, Shoichi

AU - Funaki, Yoshihito

AU - Hiraoka, Kotaro

AU - Baba, Toru

AU - Sugeno, Naoto

AU - Yoshida, Shun

AU - Kobayashi, Junpei

AU - Kobayashi, Michiko

AU - Tano, Ohito

AU - Ishiyama, Shun

AU - Nakamura, Takaaki

AU - Nakashima, Ichiro

AU - Mugikura, Shunji

AU - Iwata, Ren

AU - Taki, Yasuyuki

AU - Furukawa, Katsutoshi

AU - Arai, Hiroyuki

AU - Furumoto, Shozo

AU - Tashiro, Manabu

AU - Yanai, Kazuhiko

AU - Kudo, Yukitsuka

AU - Takeda, Atsushi

AU - Aoki, Masashi

N1 - Publisher Copyright: Copyright © 2021 Ezura, Kikuchi, Okamura, Ishiki, Hasegawa, Harada, Watanuki, Funaki, Hiraoka, Baba, Sugeno, Yoshida, Kobayashi, Kobayashi, Tano, Ishiyama, Nakamura, Nakashima, Mugikura, Iwata, Taki, Furukawa, Arai, Furumoto, Tashiro, Yanai, Kudo, Takeda and Aoki.

PY - 2021/11/29

Y1 - 2021/11/29

N2 - Introduction: We aimed to determine whether in vivo tau deposits and monoamine oxidase B (MAO-B) detection using 18F-THK5351 positron emission tomography (PET) can assist in the differential distribution in patients with corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), and Alzheimer’s disease (AD) and whether 18F-THK5351 retention of lesion sites in CBS and PSP can correlate with clinical parameters. Methods: 18F-THK5351 PET was performed in 35 participants, including 7, 9, and 10 patients with CBS, PSP, and AD, respectively, and 9 age-matched normal controls. In CBS and PSP, cognitive and motor functions were assessed using the Montreal Cognitive Assessment, Addenbrooke’s Cognitive Examination–Revised, and Frontal Assessment Battery, Unified Parkinson’s Disease Rating Scale Motor Score, and PSP Rating Scale. Results: 18F-THK5351 retention was observed in sites susceptible to disease-related pathologies in CBS, PSP, and AD. 18F-THK5351 uptake in the precentral gyrus clearly differentiated patients with CBS from those with PSP and AD. Furthermore, 18F-THK5351 uptake in the inferior temporal gyrus clearly differentiated patients with AD from those with CBS and PSP. Regional 18F-THK5351 retention was associated with the cognitive function in CBS and PSP. Conclusion: Measurement of the tau deposits and MAO-B density in the brain using 18F-THK5351 may be helpful for the differential diagnosis of tauopathies and for understanding disease stages.

AB - Introduction: We aimed to determine whether in vivo tau deposits and monoamine oxidase B (MAO-B) detection using 18F-THK5351 positron emission tomography (PET) can assist in the differential distribution in patients with corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), and Alzheimer’s disease (AD) and whether 18F-THK5351 retention of lesion sites in CBS and PSP can correlate with clinical parameters. Methods: 18F-THK5351 PET was performed in 35 participants, including 7, 9, and 10 patients with CBS, PSP, and AD, respectively, and 9 age-matched normal controls. In CBS and PSP, cognitive and motor functions were assessed using the Montreal Cognitive Assessment, Addenbrooke’s Cognitive Examination–Revised, and Frontal Assessment Battery, Unified Parkinson’s Disease Rating Scale Motor Score, and PSP Rating Scale. Results: 18F-THK5351 retention was observed in sites susceptible to disease-related pathologies in CBS, PSP, and AD. 18F-THK5351 uptake in the precentral gyrus clearly differentiated patients with CBS from those with PSP and AD. Furthermore, 18F-THK5351 uptake in the inferior temporal gyrus clearly differentiated patients with AD from those with CBS and PSP. Regional 18F-THK5351 retention was associated with the cognitive function in CBS and PSP. Conclusion: Measurement of the tau deposits and MAO-B density in the brain using 18F-THK5351 may be helpful for the differential diagnosis of tauopathies and for understanding disease stages.

KW - Alzheimer’s disease (AD)

KW - F-THK5351

KW - corticobasal syndrome (CBS)

KW - monoamine oxidase B (MAO-B)

KW - positron emission tomography (PET)

KW - progressive supranuclear palsy (PSP)

KW - tau deposits

KW - tauopathy

UR - http://www.scopus.com/inward/record.url?scp=85121385073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85121385073&partnerID=8YFLogxK

U2 - 10.3389/fnagi.2021.761010

DO - 10.3389/fnagi.2021.761010

M3 - Article

AN - SCOPUS:85121385073

SN - 1663-4365

VL - 13

JO - Frontiers in Aging Neuroscience

JF - Frontiers in Aging Neuroscience

M1 - 761010

ER -

¹⁸F-THK5351 Positron Emission Tomography Imaging in Neurodegenerative Tauopathies

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this